Your browser doesn't support javascript.
loading
A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML.
Gleixner, Karoline V; Sadovnik, Irina; Schneeweiss, Mathias; Eisenwort, Gregor; Byrgazov, Konstantin; Stefanzl, Gabriele; Berger, Daniela; Herrmann, Harald; Hadzijusufovic, Emir; Lion, Thomas; Valent, Peter.
Afiliação
  • Gleixner KV; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Austria.
  • Sadovnik I; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria.
  • Schneeweiss M; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Austria.
  • Eisenwort G; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Austria.
  • Byrgazov K; Children's Cancer Research Institute (CCRI), Vienna, Austria.
  • Stefanzl G; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Austria.
  • Berger D; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria.
  • Herrmann H; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Austria; Department of Radiation Therapy, Medical University of Vienna, Austria.
  • Hadzijusufovic E; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Austria; Department/Clinic for Companion Animals and Horses, Clinic for Small Animals, Clinical
  • Lion T; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Austria; Children's Cancer Research Institute (CCRI), Vienna, Austria; Department of Pediatrics, Medical University of Vienna, Austria.
  • Valent P; Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Austria. Electronic address: peter.valent@meduniwien.ac.at.
Leuk Res ; 78: 36-44, 2019 03.
Article em En | MEDLINE | ID: mdl-30711891
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas de Fusão bcr-abl / Resistencia a Medicamentos Antineoplásicos Limite: Humans Idioma: En Revista: Leuk Res Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas de Fusão bcr-abl / Resistencia a Medicamentos Antineoplásicos Limite: Humans Idioma: En Revista: Leuk Res Ano de publicação: 2019 Tipo de documento: Article